Otros idiomas Bristol-Myers Squibb Company Deutsche Boerse AG

Acciones

BRM

US1101221083

Mercado cerrado - Deutsche Boerse AG Otros sitios de cotización 15:54:29 21/06/2024			Varia. Cinco días.	Varia. 1 de enero.
38,93 ^EUR	+1,91 %		-0,05 %	-16,46 %

22/06	Bristol Myers Squibb anuncia la aprobación acelerada por la FDA de EE.UU. de KRAZATI®? (adagrasib) en combinación con cetuximab para pacientes adultos con cáncer colorrectal (CCR) localmente avanzado o metastásico con mutación G12C de KRAS previamente tratado	CI
21/06	La terapia contra el cáncer colorrectal de Bristol-Myers Squibb recibe la aprobación de la FDA	MT

Otros idiomas

Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!

Inscripción 100% Gratuita

Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)	22/06
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer	22/06
Bristol-Myers Squibb's Colorectal Cancer Therapy Receives FDA Approval	21/06
US FDA approves Bristol Myers' colorectal cancer therapy	21/06
Bristol-Myers Squibb Says EMA Validates Application for Subcutaneous Opdivo	21/06
Bristol Myers : demande validée pour Opdivo sous-cutané	21/06
European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab	21/06
Bristol Myers Squibb Announces European Medicines Agency Validates Extension Application to Introduce New Route of Administration (Subcutaneous Use) for Opdivo	21/06
Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024	20/06
Bristol Myers : l'ex-CEO d'Agilent rejoint le conseil	19/06
Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors	18/06
Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024	18/06
Immunocore Randomizes First Patient in Phase 3 Trial of Cutaneous Melanoma Combination Treatment	18/06
Bristol Myers Squibb Keeps Quarterly Dividend at $0.60 a Share, Payable Aug. 1 to Shareholders of Record July 5	18/06
Bristol Myers : dividendes décidés par le conseil	18/06
Bristol Myers Squibb Announces Dividend	18/06
Bristol Myers Squibb Declares A Quarterly Dividend, Payable on August 1, 2024	18/06
Bristol Myers : approbation de la FDA pour un traitement	14/06
Bristol-Myers Squibb's Augtyro Gets FDA Accelerated Approval for Treatment of Solid Tumors	13/06
Bristol Myers Squibb's Augtyro Gets FDA Accelerated Approval	13/06

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Titulares

Christopher Boerner, CEO de Bristol-Myers: la cartera de 16 tratamientos, la neurociencia y la oncología en el punto de mira

09 de enero 2024 a las 19:06